Nox Peptides Announces Expanded Research Focus on BPC-157 and GHK-Cu in Canada

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Nox Peptides Announces Expanded Research Focus on BPC-157 and GHK-Cu in CanadaAuthor of the article:Toronto, ON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nox Peptides has announced an expanded focus on research-use peptide compounds in Canada, highlighting BPC-157 and GHK-Cu as part of its ongoing efforts to support laboratory and preclinical research involving peptide-based compounds.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe company said the update reflects continued interest from researchers in understanding peptide biology, cellular mechanisms and related preclinical research areas.Nox Peptides Expands Research-Focused Peptide PortfolioThis advertisement has not loaded yet, but your article continues below.As part of the announcement, Nox Peptides is placing greater focus on BPC-157 and GHK-Cu within its research-oriented portfolio.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againBPC-157 has been investigated in preclinical research involving biological and cellular processes. Existing laboratory research has examined various mechanisms associated with the compound, contributing to broader scientific interest in peptide-related research.Nox Peptides provides BPC-157 strictly as a research-use compound and does not position it as a medicine, dietary supplement or treatment.GHK-Cu Continues to Attract Research InterestThe company is also highlighting GHK-Cu, a naturally occurring copper-binding peptide that has been examined in scientific literature for several decades.Research involving GHK-Cu has explored areas including cellular activity, fibroblast-associated processes, collagen-related mechanisms and other biological pathways. The continued study of the compound contributes to broader research into peptide biology and cellular signaling.Nox Peptides said GHK-Cu is supplied for qualified research and laboratory applications and is not intended for human use.This advertisement has not loaded yet, but your article continues below.Focus on Research Documentation and Laboratory PracticesAlongside its expanded research focus, Nox Peptides is emphasizing the importance of responsible research-material handling and appropriate laboratory procedures.Researchers evaluating peptide compounds may consider factors such as product documentation, analytical information, batch consistency, storage requirements and laboratory handling procedures when selecting materials for scientific work.The company encourages qualified researchers and laboratories to review available product documentation and follow applicable institutional requirements, safety procedures and Canadian regulations.Supporting Peptide Research in CanadaThrough its research-focused portfolio, Nox Peptides aims to support laboratories and scientific researchers investigating peptide compounds in preclinical and laboratory environments.The company said its approach remains centered on research-use materials, product information and responsible handling practices rather than therapeutic or consumer applications.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.BPC-157 and GHK-Cu are supplied for research purposes only. They are not intended for human consumption, diagnosis, treatment or prevention of disease.Nox Peptides provides research-use peptide compounds for laboratory and scientific applications. The company focuses on research-oriented sourcing and providing information relevant to researchers evaluating peptide compounds for scientific investigation.Media Contact: Nox PeptidesWebsite: https://noxpeptides.ca/ Email : info@noxpeptides.st/Note : Information contained on this page is published by SP Tech Solutions and content provided by authorized third party content provider. SP Tech Solutions and this Site make no warranties or representations in connection therewith.Nox Peptides Website: https://noxpeptides.ca/ Email : info@noxpeptides.st/This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.